Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK negative
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(4)
News
Trials
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Filter by
Latest
12ms
ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma | Blood | American Society of Hematology https://t.co/r3X6TfGAVp (@ixazebe)
12 months ago
ALK (Anaplastic lymphoma kinase) • JAK2 (Janus kinase 2)
|
ALK negative • JAK2 rearrangement
2years
Great work by @FordePatrick & colleagues. This trial has now established clear role for #immunotherapy in almost all stages of #EGFR/#ALK negative #NSCLC (early-stage neoadjuvant; early-stage adjuvant; locally advanced; metastatic). #PDL1 expression correlated w/ outcomes in all! (@ns_chd)
2 years ago
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK negative
2years
Based on the recent neo-adjuvant data and approval of Chemo-IO (#CM816) for Stage Ib-IIIA NSCLC, EGFR/ALK negative, what would you be doing in your clinical practice? In neo-adj settings, would you offer: #LCSM @FordePatrick @n8pennell @CharuAggarwalMD @JackWestMD @DrJNaidoo (@OncBrothers)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
ALK negative
2years
Similar situation now with a 50 yo male former smoker, no other comorbidities. lung adenocarcinoma, EGFR/ALK negative, PD-L1 20%. Stage IIIB (T4N2 by 7th and 8th AJCC Ed) VATS RUL lobectomy after neoadjuvant chemo-IO. pCR Remains NED (cc’d @DoctorJSpicer: again no N2 pics 🙏) (@Tony_Calles)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 negative • ALK negative
almost3years
IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY. Largest study to date... no impact of DUSP22 rearr on PFS. #16icml https://t.co/JI27UQtgUx (@timfenske)
almost 3 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK negative
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login